Print

Acorda Therapeutics (ACOR) Provides Corporate Update at 31st Annual J.P. Morgan Healthcare Conference  
1/7/2013 6:24:51 AM

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg unaudited net sales for the fourth quarter of 2012 were $73 million and unaudited AMPYRA 2012 full-year net sales were $266 million. These results are subject to completion of the Company’s year-end audit.
//-->